Dauer, 020818 WIWC, 2014-003387
Case Date | February 08, 2018 |
Court | Wisconsin |
The medical proof established applicant was sensitized to BPA-epi and BPF-epi; he did not react to the smaller BPA and, unless the test reflects a false negative, the test indicates that he was not allergic to the monomeric BPA.2. Delete the last sentence of the second full paragraph on page 5. Memorandum Opinion The applicant, born January 3, 1962, worked for Grede Foundries for about 13 years, beginning in 1999. For the last six years of his employment, he was a molding operator. He developed a set of dermatological symptoms in 2012, characterized by swelling around the eyes, a rash and flaking skin on the face, neck, hands, arms and chest, and photosensitive skin eruptions. The rash and flaking skin started while he was away from work on vacation in July 2012. He was referred by his primary care physician to the UW dermatology department. An allergy was suspected, so the applicant underwent patch testing. It revealed sensitivity to Bisphenol-A/epichlorohydrin and Bisphenol-F/epichlorohydrin (BPA-epi and BPF-epi), which are compounds found in some epoxy resins, but no sensitivity to the monomer form of BPA. Dr. Rita Lloyd, chief of dermatology at UW recorded the following assessment and plan on October 15, 2012:
Contact allergy to epoxy resin (bisphenol-A/epichlorohydrin and bisphenol-F/epichlorohydrin) evolving into chronic actinic dermatitis.[Dr. Lloyd sent letters to the applicant’s employer to find out if the applicant had been exposed to epoxy resin in the workplace. The manufacturer of a product called SigmaCure 7252, which had been used at the plant until May 2012, stated that the product contained 2% bisphenol A. Dr. Lloyd opined in November 2012 that the applicant’s dermatitis was triggered by exposure to the heated gaseous form of this epoxy resin monomer. The applicant was treated with an immunosuppressant called CellCept. In March 2013 the applicant underwent an independent medical evaluation conducted by Dr. Thomas Jetzer. In his report on April 12, 2013, Dr. Jetzer noted that the applicant’s patch testing showed allergies to bisphenol A in some form, and that the most likely agent was SigmaCure 7252. He found no basis to dispute Dr. Lloyd’s opinion that the condition was occupation-related. He also noted that the condition seemed to be controlled by CellCept. In September 2013 the...2 ] He did not react to bisphenol-A as this is a monomer; it is the polymer resin (polymer of either bisphenol A or F) that is implicated in his dermatitis…
To continue reading
Request your trial